search
Back to results

mHealth for Diabetes Adherence Support (mDAS)

Primary Purpose

Diabetes Mellitus, Type 2

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
mHealth for Diabetes Adherence Support
Sponsored by
University of Illinois at Chicago
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional health services research trial for Diabetes Mellitus, Type 2 focused on measuring Diabetes Mellitus, Type 2, Medication Adherence, Telemedicine, Community Health Workers, Pharmacists, Mobile Health

Eligibility Criteria

21 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Self-identified as Latino/Hispanic or African-American
  • Verbal fluency in English or Spanish
  • Latest A1c ≥ 8.0% (within 3 mo)
  • History of Type 2 Diabetes (> 1 year)
  • Between the ages of 21 and 75 years
  • Unlimited mobile phone/text messaging plan with ability to reply to text messages
  • Home environment capable of video conferencing with wireless signal
  • Receives primary care at UI Health clinical site for at least one year, with one visit during past year
  • Able and willing to provide informed consent (agree to data collection requirements, accept randomization, agree to home visitation with HC and pharmacist involvement, and participate for two years)

Exclusion Criteria:

  • Unable to verbalize comprehension of study or impaired decision making
  • Family/household member already participating in same study
  • Currently receiving regular pharmacist support through Medication Therapy Management or equivalent
  • History of, or planned, gastric bypass or transplant surgery
  • History of bipolar or psychotic disorder
  • Other severe comorbidities that require complex, aggressive, or palliative treatment, e.g., stage 4 or greater renal disease, liver failure, cancer (other than nonmelanoma skin cancer), terminal illness
  • Investigator discretion for safety concerns

Sites / Locations

  • University of Illinois Hospital and Health Sciences System

Arms of the Study

Arm 1

Arm 2

Arm Type

No Intervention

Experimental

Arm Label

Usual Care

mHealth for Diabetes Adherence Support

Arm Description

Participants will receive their usual care for the first year of their enrollment in the study. They will receive a referral to a diabetes educator and a clinical pharmacist, a one-page sheet of contact information for their healthcare providers, and paper-based, low-literacy diabetes information. After one year, they will change to the mDAS intervention arm for one year.

Participants will receive in-person support from a health coach and a clinical pharmacist with whom they will meet with regularly via videoconference. After one year, participants who have completed the mDAS intervention will be monitored for an additional year with usual care to evaluate maintenance.

Outcomes

Primary Outcome Measures

Hemoglobin A1c

Secondary Outcome Measures

Self-reported medication adherence
A 3-item questionnaire will be administered to measure adherence to diabetes medications.
Blood Pressure
LDL Cholesterol
LDL Cholesterol will be measured as part of a Full Lipid profile blood test.
Diabetes Self-Management
Self-management will be measured by the revised 11-item Summary of Diabetes Self Care Activities questionnaire.
Health related quality of life
General health-related quality of life will be measured by the EuroQOL 5D (EQ-5D).
Diabetes related quality of life
Diabetes-related quality of life will be measured by the Diabetes Distress Screening Instrument (DDS4).
Depression
Measured with the nine-item Patient Health Questionnaire (PHQ-9)
Alcohol Misuse
Measured using the 3-item AUDIT-C questionnaire
BMI
Height and weight will be taken at each time point to determine BMI
Social Support
4-item questionnaire measuring satisfaction with support from friends, family and health care team
Diabetes Self-efficacy
8 -item questionnaire measuring confidence in diabetes self-management skills

Full Information

First Posted
December 5, 2016
Last Updated
June 9, 2023
Sponsor
University of Illinois at Chicago
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
search

1. Study Identification

Unique Protocol Identification Number
NCT02990299
Brief Title
mHealth for Diabetes Adherence Support
Acronym
mDAS
Official Title
mHealth for Diabetes Adherence Support
Study Type
Interventional

2. Study Status

Record Verification Date
June 2023
Overall Recruitment Status
Completed
Study Start Date
March 24, 2017 (Actual)
Primary Completion Date
January 7, 2022 (Actual)
Study Completion Date
January 7, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Illinois at Chicago
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this research study is to determine the benefit and cost of including health coaches, clinical pharmacists and mobile health (mHealth) tools such as text messaging and videoconferencing in diabetes management support services for African-Americans and Latinos with uncontrolled Type 2 Diabetes.
Detailed Description
Many African-Americans and Latinos with diabetes do not achieve recommended diabetes goals placing them at high risk for complications. Team-based models of care can help in reaching goals of therapy. Additionally, mobile health (mHealth) technologies can further improve outcomes among those more difficult to reach. This study will evaluate the impact of a team-based, mHealth intervention designed to improve medication adherence, healthy eating, and physical activity behaviors. The investigators will compare this mHealth approach with usual care. Clinical pharmacists and health coaches (HC) will deliver our proposed team-based intervention. mHealth delivery includes mobile phone text messaging, secure videoconferencing, and HC home visits. Pharmacists will focus on medication reconciliation and adherence. Health coaches will help identify psychosocial and environmental challenges to adherence in a culturally-sensitive manner. Together, they can assist in goal-setting, problem-solving, negotiation of competing priorities, and provide social support leveraging mHealth technologies. Preliminary data from previous research by the research team supports the role of health coaches partnering with clinic- based pharmacists in improving diabetes outcomes in minorities. In the proposed mHealth intervention, patient- pharmacist videoconferencing will eliminate the need for in-person visits with a pharmacist, which is impractical for many low-income patients. In addition, pilot work suggests that text messaging is a preferable means of communication and may facilitate more frequent contact with patients. This is a randomized, controlled trial to evaluate the effectiveness of an mHealth diabetes adherence support intervention delivered by clinical pharmacists and health coaches. The research team will randomize 220 patients through UI Health to either: (1) mHealth diabetes adherence support through clinical pharmacists and health coaches; or (2) usual care. After one year, patients completing the mHealth intervention will be monitored for an additional year while the usual care group receives the mHealth approach. Outcomes include medication adherence, hemoglobin A1c, blood pressure, and LDL-cholesterol levels. The specific aims include: (1) evaluate the effectiveness of an mHealth diabetes adherence support intervention delivered by clinical pharmacists and health coaches to African-American and Latino adults with uncontrolled type 2 diabetes; (2) evaluate the maintenance of improved diabetes behaviors as well as clinical outcomes one year after completing the intervention; (3) evaluate the cost and cost-effectiveness of mHealth diabetes adherence support compared to usual care; and (4) evaluate the reach, adoption, and implementation of mHealth diabetes adherence support based on the RE-AIM framework.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2
Keywords
Diabetes Mellitus, Type 2, Medication Adherence, Telemedicine, Community Health Workers, Pharmacists, Mobile Health

7. Study Design

Primary Purpose
Health Services Research
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
A 2-arm, parallel, randomized controlled trial. Patients are randomized 1:1 to (1) mHealth diabetes adherence support intervention for one year and monitored with usual care for the second year, or (2) wait-list usual care for one year, then intervention during the second year.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
221 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Usual Care
Arm Type
No Intervention
Arm Description
Participants will receive their usual care for the first year of their enrollment in the study. They will receive a referral to a diabetes educator and a clinical pharmacist, a one-page sheet of contact information for their healthcare providers, and paper-based, low-literacy diabetes information. After one year, they will change to the mDAS intervention arm for one year.
Arm Title
mHealth for Diabetes Adherence Support
Arm Type
Experimental
Arm Description
Participants will receive in-person support from a health coach and a clinical pharmacist with whom they will meet with regularly via videoconference. After one year, participants who have completed the mDAS intervention will be monitored for an additional year with usual care to evaluate maintenance.
Intervention Type
Behavioral
Intervention Name(s)
mHealth for Diabetes Adherence Support
Other Intervention Name(s)
mDAS
Intervention Description
Participants will be paired with a health coach who will provide ongoing support and resources in medication and lifestyle adherence and diabetes self-management. The health coach will perform regular home visits, telephone support and tailored text-messages based on the participant's preferences and needs. They will help assess barriers to adherence and use motivational interviewing to help patients set goals and create action plans. They will also facilitate videoconferences with an assigned clinical pharmacist who will provide consultation on medication use, reconciliation and adherence, identify therapeutic goals and formulate an approved plan of care.
Primary Outcome Measure Information:
Title
Hemoglobin A1c
Time Frame
24 months
Secondary Outcome Measure Information:
Title
Self-reported medication adherence
Description
A 3-item questionnaire will be administered to measure adherence to diabetes medications.
Time Frame
24 months
Title
Blood Pressure
Time Frame
24 months
Title
LDL Cholesterol
Description
LDL Cholesterol will be measured as part of a Full Lipid profile blood test.
Time Frame
24 months
Title
Diabetes Self-Management
Description
Self-management will be measured by the revised 11-item Summary of Diabetes Self Care Activities questionnaire.
Time Frame
24 months
Title
Health related quality of life
Description
General health-related quality of life will be measured by the EuroQOL 5D (EQ-5D).
Time Frame
24 months
Title
Diabetes related quality of life
Description
Diabetes-related quality of life will be measured by the Diabetes Distress Screening Instrument (DDS4).
Time Frame
24 months
Title
Depression
Description
Measured with the nine-item Patient Health Questionnaire (PHQ-9)
Time Frame
24 months
Title
Alcohol Misuse
Description
Measured using the 3-item AUDIT-C questionnaire
Time Frame
24 months
Title
BMI
Description
Height and weight will be taken at each time point to determine BMI
Time Frame
24 months
Title
Social Support
Description
4-item questionnaire measuring satisfaction with support from friends, family and health care team
Time Frame
24 months
Title
Diabetes Self-efficacy
Description
8 -item questionnaire measuring confidence in diabetes self-management skills
Time Frame
24 months
Other Pre-specified Outcome Measures:
Title
Healthcare utilization
Description
This will include costs associated with hospital admissions, emergency room and outpatient visits and prescription medications.
Time Frame
24 months
Title
Program cost
Description
This will include costs associated with the intervention including pharmacists and health coaches (training, salaries, implementation), educational materials, tablet computers and associated data service, text messaging and videoconferencing.
Time Frame
24 months
Title
Health Coach Satisfaction
Description
A survey administered to the patient for feedback on their assigned health coach.
Time Frame
1 year after health coach assignment

10. Eligibility

Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Self-identified as Latino/Hispanic or African-American Verbal fluency in English or Spanish Latest A1c ≥ 8.0% (within 3 mo) History of Type 2 Diabetes (> 1 year) Between the ages of 21 and 75 years Unlimited mobile phone/text messaging plan with ability to reply to text messages Home environment capable of video conferencing with wireless signal Receives primary care at UI Health clinical site for at least one year, with one visit during past year Able and willing to provide informed consent (agree to data collection requirements, accept randomization, agree to home visitation with HC and pharmacist involvement, and participate for two years) Exclusion Criteria: Unable to verbalize comprehension of study or impaired decision making Family/household member already participating in same study Currently receiving regular pharmacist support through Medication Therapy Management or equivalent History of, or planned, gastric bypass or transplant surgery History of bipolar or psychotic disorder Other severe comorbidities that require complex, aggressive, or palliative treatment, e.g., stage 4 or greater renal disease, liver failure, cancer (other than nonmelanoma skin cancer), terminal illness Investigator discretion for safety concerns
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ben S Gerber, MD, MPH
Organizational Affiliation
University of Illinois at Chicago
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Lisa K Sharp, PhD
Organizational Affiliation
University of Illinois at Chicago
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Illinois Hospital and Health Sciences System
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60612
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
33688847
Citation
Sharp LK, Biggers A, Perez R, Henkins J, Tilton J, Gerber BS. A Pharmacist and Health Coach-Delivered Mobile Health Intervention for Type 2 Diabetes: Protocol for a Randomized Controlled Crossover Study. JMIR Res Protoc. 2021 Mar 10;10(3):e17170. doi: 10.2196/17170.
Results Reference
result

Learn more about this trial

mHealth for Diabetes Adherence Support

We'll reach out to this number within 24 hrs